CYPHERPUNK TECHNOLOGIES INC. (CYPH): M&A transaction — Leap Therapeutics removes requirement to file Flame Biosciences financials

CYPHERPUNK TECHNOLOGIES INC.

Amendment to 8-K (filed Jan 23, 2023) deletes references to filing financial statements and pro forma info for Flame Biosciences acquisition.
Company determined financial statements for the January 2023 acquisition are not required under Item 9.01 of Form 8-K.
No change to acquisition terms or closing date; procedural update only.

item 2.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

M&A Transactions SEC 8-K Item 2.01/5.01 confidence 0.7

CYPHERPUNK TECHNOLOGIES INC. completed an acquisition involving Flame Biosciences, Inc. (closed 2023-01-23).

Action: acquisition
Counterparty: Flame Biosciences, Inc.
Closing: 2023-01-23

Exact text from the filing

On January 23, 2023, Leap Therapeutics, Inc. (the “Company”) filed a Current Report on Form 8-K (the “Original Form 8-K”) disclosing the Company’s acquisition of Flame Biosciences, Inc., a Delaware corporation, pursuant to an Agreement and Plan of Merger, dated January 17, 2023 (the “Acquisition”).

View on SEC.gov

31 m&a transactions filed in the last 30 days. Browse all m&a transactions →

CYPHERPUNK TECHNOLOGIES INC. filing history →

Source: SEC EDGAR

accession 0001104659-23-036607

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.